tiprankstipranks
Advertisement
Advertisement
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
PremiumRatingsBuy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
1M ago
Tarsus Pharmaceuticals doses first participant in TP-05 trial
Premium
The Fly
Tarsus Pharmaceuticals doses first participant in TP-05 trial
1M ago
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
1M ago
Tarsus Pharmaceuticals rises 11.6%
PremiumThe FlyTarsus Pharmaceuticals rises 11.6%
2M ago
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
2M ago
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
Premium
Ratings
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
2M ago
Tarsus Pharmaceuticals Adds Industry Veteran to Board
PremiumCompany AnnouncementsTarsus Pharmaceuticals Adds Industry Veteran to Board
3M ago
Tarsus Pharmaceuticals appoints Pyott to Board of Directors
Premium
The Fly
Tarsus Pharmaceuticals appoints Pyott to Board of Directors
3M ago
Tarsus Pharmaceuticals price target raised to $68 from $51 at Goldman Sachs
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $68 from $51 at Goldman Sachs
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100